Not checked for notices yet.
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain and 14 more
OncoImmunology · 2018
doi:10.1080/2162402x.2018.1472195
Cited by papers we hold 1
- Emerging agents and regimens for AML · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.